Description of the disease
The spinal muscular atrophies are a clinically and genetically heterogeneous group of neuromuscular disorders caused by degeneration of anterior horn cells. In proximal spinal muscular atrophy (SMA), the muscles of the extremities closest to the trunk are more severely and earlier affected. SMA is clinically classified into four types: acute, intermediate, mild, and adult (SMA types I, II, III, and IV, respectively). 1, 2 Used nomenclature is summarised in Table   1 . Criteria for clinical classification of SMA I, II, and III patients are summarised in Table 2 . 49 With an estimated incidence of *1/10 000, 3,4,46 ± 48 and a carrier frequency of 1/40 ± 1/60 5, 6 the SMAs are among the most frequent autosomal recessive hereditary disorders, and apparently the incidence is similar in different populations studied. The SMA 5q13 region shows a complex structure at the genomic level, including a 500-kilobase pair duplication and inversion. 7 The survival of motor neuron (SMN) gene exists as two homologues, at least one telomeric gene (SMN1) and in the vast majority of chromosomes at least one centromeric gene (SMN2) per chromosome in normal (non-carrier) individuals, although also chromosomes with an intact SMN1 gene exist that lack SMN2. 7 The two SMN genes (SMN1 and SMN2) are highly homologous and contain only five base-pair differences that occur within their 3' regions. 8 These differences in exons 7 and 8 are used to distinguish SMN1 and SMN2 in DNA analysis. Deletions of the SMN1 gene appear to be directly involved in SMA, 7 since exon(s) 7
(and 8) of SMN1 are undetectable in over 95% of patients, irrespective of their clinical type, 7,9 ± 12,14 either as a result of identification of several small mutations in the SMN1 gene in patients without a deleted or sequence-converted SMN1 allele 7,17 ± 25,29 provide strong evidence that the SMN1 gene is the primary SMA-determining gene. The clinical phenotype of SMA appears to be partly determined by the underlying mutational mechanism. Most cases of SMA type I result from homozygous gene-deletion events, whereas the milder forms of the disease, SMA types II and III, are more likely to result from gene conversion of SMN1 into SMN2; SMA type II from a gene conversion event in one allele in addition to a hemizygous deletion event in the other allele; in SMA type III from gene conversions in both alleles. 7, 13, 15, 16, 26, 27 As a result, patients suffering from the milder forms of SMA carry more copies of the SMN2 gene. In the Smn17/7SMN2 mouse models, multiple copies of human SMN2 seem to prevent SMA development in Smn1-deleted animals (almost) completely. 38, 39 
Common reasons for referral
Confirmation of the clinical diagnosis or suspicion of SMA by the detection of homozygous SMN1 exons 7 and exon 8 deletions is fast, inexpensive, and reliable. The clinical sensitivity is around 95%, the clinical specificity is over 99%. Therefore, no restricting clinical criteria are warranted before undertaking DNA analysis. This is certainly so in neonatal cases in which a rapid molecular analysis and diagnosis may render more invasive procedures (ie, a muscle biopsy) unnecessary. A different situation exists when hemizygous SMN1 deletion analysis or subtle mutation analysis is asked for. Our guidelines are summarised in Table 3 .
Other reasons for referral include carrier detection by direct hemizygous SMN1 exon 7 deletion analysis and/or indirect linkage analysis. Carrier detection by direct analysis is indicated in siblings and close relatives of SMA patients with a homozyous SMN1 exons 7 and 8 deletion, in parents of SMA patients who died, and in partners of ascertained carriers without positive family history for SMA. Indirect analysis can only be applied in family members of a patient, assuming that an adequate number of family members are available for analysis to establish linkage phase. Direct analysis is strongly recommended in these cases.
A third indication for DNA analysis is prenatal analysis. This is often requested by parents of a SMA patient, and may also be indicated for couples who have been shown to be carriers of a mutant SMN1 allele, or for couples of an affected patient with SMA with an identified carrier, which is not a rare situation in SMA type III.
Approaches
General strategy 1 Appropriate patients selected for molecular analysis. 2 Confirmation of clinical diagnosis by analysis of homozygous SMN1 exon 7 deletion. 
Confirmation of clinical diagnosis
The ability to detect deletions in SMN1 means that testing to confirm a diagnosis of SMA in affected individuals is possible. The presence of a homozygous deletion of exons 7 and 8 is consistent with a diagnosis of SMA given that there are clinical grounds for suspecting SMA. The absence of a homozygous SMN1 deletion does not rule out a diagnosis of SMA since approximately 6% of cases are known not to have a homozygous SMN1 deletion, a proportion of those SMA patients will have a subtle mutation in one or extremely rarely in both SMN1 alleles instead. 45 In routine SMN1
testing, a DNA-laboratory often has no or only scarce clinical data on a given patient. In that case, whenever a homozygous SMN1 deletion is not found in a patient, one should doubt the diagnosis of SMA. The presence of a hemizygous SMN1 exon 7 deletion identified by a quantitative determination of the number of SMN1 exon 7 copies may provide further support for the diagnosis of SMA (appr. 95 ± 96% of SMA patients have at least a heterozygous SMN1 deletion). Nevertheless, formal confirmation of the clinical diagnosis in those cases can only be obtained after identification of subtle SMN1 mutation(s).
The clinical subtype of SMA appears to be determined (in part) by the nature of the SMN1 mutations. In general, SMA type I is associated with deletions in both alleles, SMA type 2 with a deletion in one, and a gene conversion in the other allele, and SMA type 3 with gene conversions in both alleles. The molecular identification of absence of exon 7 in both alleles of SMN1 in the presence of one or two copies of SMN1 exon 8 is indicative for such gene conversions. However, these data, when available, can at present not be used to predict the clinical course of the disease.
Carrier testing
Several papers including those by McAndrew et al, 21 Wirth et al, 29 Gerard et al 41 29, 30 Since the frequency of carriers with two SMN1 genes per chromosome is 4%, compared to only 1% of parents being non-carrier due to a de novo mutation, no direct conclusions should be drawn from apparently normal results in carrier testing in parents of affected individuals. This problem can be resolved by the identification of a recombination event associated with the de novo mutation by indirect analysis, eg, by using the multicopy markers Ag1-CA and C212 32 or other flanking markers. Alternatively, the occurrence of a de novo deletion can be confirmed by normal SMN1 dosage in the parents of the apparent non-carrier parent, ie, two of the grandparents of the affected child. When two SMN1 genes on a single chromosome (opposite to a chromosome lacking an intact SMN1 gene) cause the normal SMN1 dosage in the carrier parent, one grandparent will have an SMN1 dosage compatible with a single SMN1 gene. The other grandparent will have an SMN1 dosage compatible with three SMN1
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Quantitative SMN1 exon 7 analysis should be restricted to families in which a homozygous SMN1 deletion has been identified in the index case, in order to prevent performing dosage analysis in relatives of patients with a SMA type phenotype not caused by SMN1. An exception could be made in parents of a deceased patient with a clinically quite clear diagnosis of SMA.
Carrier testing in relatives of SMA patients, eg, siblings and/ or uncles and aunts could also be performed by indirect analysis using flanking markers. A prerequisite is the availability of sufficient DNA samples from family members for establishing linkage phase and informativity of the markers.
Prenatal testing
Prenatal analysis is carried out preferably by direct mutation detection, eg, by testing for a homozygous SMN1 exon 7 deletion. A prerequisite is the identification of a homozygous deletion in the index patient.
Homozygous deletions of SMN1 exons 7 and 8 in unaffected haplo-identical sibs of SMA patients have been described. 10, 11, 31 Parents of a SMA patient may actually have a homozygous SMN1 deletion themselves. Although it is hard to predict whether the parental SMN1 deletion allele that had not been transmitted to the affected child may have a pathogenic effect at all, it is our opinion that it cannot be considered simply as a non-risk SMN1 allele. Such an allele should be dealt with as an allele with a potential pathogenic effect. Prenatal testing based on linkage analysis is useful in families with a clinically ascertained patient with proximal SMA without a homozygous SMN1 deletion. It is recommended that this approach should only be used when a hemizygous SMN1 deletion has been identified in the index case. An exception could be made in special cases with a clinically quite clear diagnosis of SMA and consanguinity of the parents, making homozygosity for a rare nondeletion mutant SMN1 allele in the index case more likely. Prenatal analysis in families with non-deleted patients should generally not be performed. Flanking markers may also be used to confirm the results of deletion analysis in prenatal testing, and to exclude interfering admixture of maternal cells in the foetal sample. Some laboratories prefer the use of markers from other chromosomes for exclusion of maternal admixture from foetal tissue to circumvent unwanted information about the foetal carrier status.
Linkage analysis
Linkage analysis is useful for carrier testing if quantitative deletion analysis is not feasible.
In postnatal applications, linkage-based testing of unaffected siblings, or preferably the grand-parents of the index case, may be useful to identify a possible meiotic recombination associated with a de novo deletion or rearrangement involving SMN1. Also, uniparental isodisomy may be identified by the use of flanking markers.
Some laboratories have the policy to include unaffected siblings in a linkage analysis only when necessary, in order to avoid problems with the identification of carriers in young children. However, this depends on the local situation.
Technical protocols
Analysis of homozygous SMN1 deletions Homozygous deletions of exons 7 and 8 of SMN1 can be detected by several methods including:
1 SSCP ± either on polyacrylamide (8% on 12 cm gels works well) or MDE gels. 7 Primer sequences and PCR conditions are summarised in the section`Primer Sequences'. The deletion can be visualised by silver staining of the gels as well as by radioactivity or fluorescence. 42 SSCP has the advantage that subtle mutations in the gene may be detected as well as deletions. However, the method will also identify neutral polymorphisms. A study from Wang et al 31 has shown that 4% of asymptomatic family members carry a polymorphic variant of exon 7 of SMN1 (telomeric) which looks like a homozygous deletion on SSCP gels. 2 Restriction enzyme digestion. 28, 29 For exon 7 the enzymes DraI or HinfI could be used to separate SMN1 and SMN2 in combination with specific primers, for exon 8 DdeI can be used. Primer sequences and PCR conditions are summarised in the section`Primer sequences'. These are rapid assays, and have the additional advantage that the pathogenic absence of SMN1 exons 7 and 8 is very specifically tested for.
Gene conversion can be detected by SSCP analysis, dependent on local laboratory conditions used. The restriction digest method does not differentiate between a true deletion and a gene conversion, but correctly determines absence of SMN1 exons 7 and 8 from their normal genomic position.
Some laboratories prefer to confirm exon 7 only deletions by a second, independent test (in the majority of cases absence of both exons 7 and 8 is detected; these test results confirm each other). Testing for SMN1 exon 7 is the most accurate test, and some laboratories consider testing for SMN1 exon 8 being redundant. Testing for SMN1 exon 8 only may lead to a false negative result.
It is recommended that samples from patients known to have a homozygous SMN1 deletion (positive reference samples) as well as samples known to contain intact SMN1 allele(s) (negative reference samples) are always digested and run in parallel on gels to monitor completeness of the
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Dosage analysis of hemizygous SMN1 deletions
A number of quantitative assays based on competitive amplification of SMN1 and SMN2 exons 7 to determine their gene-copy number have been described. 21, 29, 30, 42 Primer sequences and PCR conditions are summarised in the sectioǹ Primer Sequences'. Technical details and pitfalls can be found in the original papers by McAndrew et al, 21 Wirth et al, 29 Gerard et al 41 and Scheffer et al. 30 The latter system makes use of fluorescently labelled primers, enabling the analysis to be performed on an automated sequencer. Reference samples with known SMN1 exon 7 copy number should be included on the gels. These assays make use of internal standard plasmids that are added to the reaction mixture for monitoring of the efficiency of the amplification. For availability of these standards and internal controls, the corresponding authors of the respective papers should be contacted. New PCR technology, eg, based on real time PCR (eg, Taqman or FRET technologies), allows the quantification of the PCR during the course of the reaction. Applications for SMA are currently under development.
Since in clinical DNA service practice the majority of the tests used are currently based on qualitative analyses, it is strongly recommended that implementation of a quantitative SMN1 assay should be preceded by a thorough validation of sensitivity and specificity by the laboratory wishing to undertake this testing.
Linkage analysis A number of informative microsatellite markers flanking the SMA gene are summarised in Table 4. 33 ± 37 It should be possible to find an informative proximal and distal marker in the majority of cases so that the overall error based on linkage with flanking markers is 51%.
There are also multi-copy markers including C212 and C272 (Ag1-CA), which lie near the 5' end of SMN1. 6, 43, 44 These can also be used although the interpretation of alleles requires considerable experience.
SMN1 subtle mutation analysis SMN1 subtle mutation analysis is beyond the scope of current routine DNA service for SMA. In cases where analysis of subtle mutations is necessary, laboratories offering this facility (eg, Bonn, Groningen) should be contacted. In these cases, the clinical diagnosis should meet the criteria formulated in Table 3 .
Primer sequences
The primer sequences are taken from the references indicated. Individuals should consult the appropriate reference for full instructions and information on primer use. While every effort has been made to ensure the accuracy of the primer sequences, individual users should confirm these sequences before use. The SMN1 exon 7 product will contain two HinfI sites; the SMN2 exon 7 product will contain one HinfI site.
SMN1 exon 8 homozygous deletion test using DdeI 541C960 and 541C1120 are used as forward and reverse primers, respectively. DdeI will cleave SMN2 exon 8 specifically.
SMN1 exon 7 dosage analysis
McAndrew et al
21
R111 and X7-Dra are used as forward and reverse primers, respectively. The reference PCR product from the CFTR gene is amplified using CF621F: 5'-AGTCAC-CAAAGCAGTACAGC-3' as forward primer, and CF621R: 5'- Guidelines for molecular analysis of SMA H Scheffer et al 488 GGGCCTGTGCAAGGAAGTGTTA-3' as reverse primer. For monitoring the efficiency of the PCR, cloned DNA of a SMN and a CFTR internal standard are added to the multiplex reaction.
Wirth et al
29 SMN7F and SMN7R are used as forward and reverse primers, respectively. The reference PCR product is amplified using CF621F and CF621R. For monitoring the efficiency of the PCR, cloned DNA of a SMN and a CFTR internal standard are added to the multiplex reaction. Appendix 1
